Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Recurrence 1Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Glioblastoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × paclitaxel-Angiopep-2 conjugate × Clear all
NCT00539344 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Angiochem Inc

Phase 1 Completed
63 enrolled
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma, Recurrence

NCT00539383 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

Angiochem Inc

Phase 1 Completed
56 enrolled
BreastCNSDermatologicGastrointestinalThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡